Equities Analysts Set Expectations for COGT FY2027 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Stock analysts at Leerink Partnrs raised their FY2027 earnings per share (EPS) estimates for Cogent Biosciences in a report released on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the technology company will earn $0.69 per share for the year, up from their previous estimate of $0.61. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.29) per share.

A number of other equities research analysts have also commented on COGT. Needham & Company LLC dropped their price target on Cogent Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday. Robert W. Baird lifted their price target on shares of Cogent Biosciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research note on Thursday, September 5th. JPMorgan Chase & Co. increased their price objective on shares of Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Cogent Biosciences in a research report on Monday, November 4th. Finally, Citigroup increased their target price on Cogent Biosciences from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Cogent Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Cogent Biosciences Trading Down 7.2 %

Shares of Cogent Biosciences stock opened at $9.65 on Friday. The stock’s fifty day simple moving average is $11.02 and its 200 day simple moving average is $9.53. The company has a market capitalization of $1.06 billion, a PE ratio of -3.89 and a beta of 1.72. Cogent Biosciences has a 12 month low of $3.67 and a 12 month high of $12.61.

Cogent Biosciences (NASDAQ:COGT) last issued its quarterly earnings data on Tuesday, November 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). During the same quarter in the previous year, the business posted ($0.64) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of COGT. Cinctive Capital Management LP raised its stake in shares of Cogent Biosciences by 91.6% during the 3rd quarter. Cinctive Capital Management LP now owns 330,419 shares of the technology company’s stock worth $3,569,000 after purchasing an additional 157,969 shares in the last quarter. Verition Fund Management LLC raised its position in Cogent Biosciences by 7.5% during the third quarter. Verition Fund Management LLC now owns 31,228 shares of the technology company’s stock worth $337,000 after acquiring an additional 2,176 shares in the last quarter. Walleye Capital LLC bought a new stake in Cogent Biosciences during the third quarter worth $6,019,000. FMR LLC lifted its stake in Cogent Biosciences by 8.1% in the third quarter. FMR LLC now owns 8,319,411 shares of the technology company’s stock valued at $89,850,000 after acquiring an additional 625,743 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Cogent Biosciences in the 3rd quarter valued at about $3,135,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.